AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.